Sign in
Taking peoplePhase 4

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

Key facts

Who runs it
Erasmus Medical Center
Where
Netherlands18 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
980 people, planned
Started
3 Jan 2025
Expected to end
1 Dec 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Double dosing of beta-lactam antibiotic
Record updated
9 January 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • ≥18 years of age
  • Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)
  • Primary infection
  • Admitted to the ICU
  • Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or greater, and a serum lac tate level greater than 2.0 mmol/L following "adequate fluid resuscitation"

Who cannot take part

  • Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)
  • Patient received the study antibiotic for more than 24 hours before inclusion
  • Patient receiving extracorporeal membrane oxygenation (ECMO)
  • Patient is already treated with a double dose of antibiotics based on suspected infection
  • Patient or legal representative not available to give informed consent within 72 hours after admittance
  • Pregnancy
  • Admittance for burn wounds
  • Enrolment in another interventional trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.

The 2 groups in the trial

  • ControlNo study treatment, for comparison

    This arm will receive standard of care according to local protocol.

  • InterventionTreatment being tested

    This arm will be treated with double dosages of beta-lactam antibiotics the first 48 hours after inclusion.

    Treatment: Double dosing of beta-lactam antibiotic

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Publications
Record updated
9 January 2025